Skip to main content
Premium Trial:

Request an Annual Quote

When Winning Jeopardy! Isn't Enough …


IBM's Watson supercomputer turned in an impressive performance on the game show Jeopardy! early last year, beating its two human competitors by a wide margin. IBM assured the Jeopardy! audience that the technology behind Watson could be used to solve a number of problems, including some related to medicine. Now, says's Jennifer Zaino, IBM has teamed up with health insurance provider WellPoint to put Watson to the task of helping doctors treat cancer. "The initial focus of the strategic partnership will be on breast, lung and colon cancers," Zaino says. "The applications to be developed will take advantage of Watson's ability to analyze tremendous amounts of structured and unstructured information to help improve the diagnosis and treatment of patients." Watson will be fed information from research studies, medical journal papers, and treatment protocols, and will hopefully distill that down to helping oncologists find personalized solutions for their patients. WellPoint hopes using Watson will drive down the cost of treating cancer patients as well as improve outcomes, and the company will be "training" Watson for its debut in the clinic, Zaino adds.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.